Acrivon Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Acrivon Therapeutics, Inc. (ACRV) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $6.12 per share as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $6.12.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $6.50.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $6.59.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $6.51.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $6.12 10-Q · filed 2026-08-12 |
| 2026-03-31 | $6.50 10-Q · filed 2026-05-13 |
| 2025-12-31 | $6.59 10-K · filed 2026-03-19 |
| 2025-09-30 | $6.51 10-Q · filed 2025-11-13 |
| 2025-06-30 | $6.46 10-Q · filed 2025-08-13 |
| 2025-03-31 | $6.22 10-Q · filed 2025-05-14 |
| 2024-12-31 | $6.15 10-K · filed 2025-03-27 |
| 2024-09-30 | $5.98 10-Q · filed 2024-11-13 |
| 2024-06-30 | $5.76 10-Q · filed 2024-08-13 |
| 2024-03-31 | $5.42 10-Q · filed 2024-05-14 |
| 2023-12-31 | $5.08 10-K · filed 2024-03-28 |
| 2023-09-30 | $2.85 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.64 10-Q · filed 2023-08-11 |
| 2023-03-31 | $2.40 10-Q · filed 2023-05-09 |
| 2022-12-31 | $2.14 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |